Compliant with Alliant

The episode delivers solid regulatory and compliance-specific information that a benefits professional should know (DOL proposed rules, CAA 2026 provisions, FTC settlements, state preemption landscape), but relies heavily on framework-laying and generalities rather than novel strategic insights. The speakers explain *what* is happening but offer limited insight into *why it matters operationally* or *how to prioritize*. Moderate density of actionable regulatory detail, but thin on contrarian or deeply practical guidance.

“the proposed rule that we're talking about that impacts PBMS is rooted in what's called ERISA 408, which is basically um, it's technical”

“plan fiduciaries then have the information they need in advance of deciding whether to go with this PBM or this service provider to decide, well that makes sense”

The episode synthesizes recent regulatory developments competently but operates within well-established compliance thinking: disclosure requirements, fiduciary duty frameworks, and ERISA preemption doctrine are standard counsel. No contrarian takes, first-principles arguments, or unexpected angles emerge. The FTC settlement discussion notes structural change but doesn't interrogate deeper questions about PBM economics or why these settlements took so long.

“recall that um, ERISA is a federal law with complete preemption, um, that applies to self funded plans, does not apply to your fully insured plans”

“any law that's going to try to directly regulate the administration or the design or network structure of the plan. That's where we see a greater likelihood for preemption”

Both speakers hold compliance roles at Alliant (director and lead attorney), suggesting relevant expertise, but the transcript reveals limited operational depth. Neither guest demonstrates hands-on pharmacy benefits management experience, vendor negotiation, or outcomes data from advising plans through PBM transitions. They speak as compliance specialists interpreting regulation, not as practitioners who have executed PBM strategy or managed significant cost outcomes. Relevant but not caliber-of-operator.

“I'm the director of the Employee Benefits Compliance Department”

“Laura is one of our lead compliance attorneys here at Alliant”

The episode lacks concrete examples, named plan outcomes, cost figures, or specific vendor behaviors. Regulatory language is cited (ERISA 408, CAA 2026 effective dates, settlement names: Express Scripts, CVS Caremark, OptumRx) but no dollar amounts, claim trends, savings/cost impacts, or real case studies ground the discussion. The speakers repeatedly defer to 'more detailed' webinars and advisors rather than providing specifics. State preemption cases are mentioned (Rutledge, Mulready, Tennessee) but not explained with detail.

“the Consolidated Appropriations act of 2026 which is legislative in nature”

“settlement with Express Scripts, which really at a very high level. Right. We don't want to get into the details here”

The conversation is collegial and well-structured by topic, but lacks sharp questioning or productive tension. Speaker A largely sets up topics and hands off; Speaker B delivers regulatory summaries without substantive pushback or follow-up. No moments where the host challenges an assumption, drills into a contradiction, or demands specificity. The tone is instructional rather than investigative. Questions are procedural ("do you want to talk about...") rather than probing.

“So I'll turn to um, to our first development. So there are a few things we're going to talk about.”

“Laura, are we good?”